Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Archives

You are currently viewing the 2001 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: esomeprazole magnesium

« Back to Dashboard

Summary for Generic Name: esomeprazole magnesium

Tradenames:1
Patents:16
Applicants:1
NDAs:1
Drug Master File Entries: see list47
Suppliers: see list12
Therapeutic Class:Gastrointestinal Agents

Pharmacology for Ingredient: esomeprazole magnesium

Tentative approvals for ESOMEPRAZOLE MAGNESIUM

Applicant Application No. Form Dosage
<disabled><disabled>CAPSULE, DELAYED RELEASE; ORAL20MG
<disabled><disabled>CAPSULE, DELAYED RELEASE; ORAL40MG

Clinical Trials for: esomeprazole magnesium

Nexium Study To Suppress Nausea During Chemotherapy
Status: Terminated Condition: Nausea

Viokase 16, Viokase16 Plus Nexium and Nexium Alone
Status: Terminated Condition: Chronic Pancreatitis

Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Status: Completed Condition: Gastroesophageal Reflux Disease

Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
Status: Completed Condition: Heartburn; Gastroesophageal Reflux Disease

Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers
Status: Completed Condition: Healthy

The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes4,636,499<disabled><disabled>
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes<disabled><disabled>
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes4,508,905<disabled><disabled>
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes6,166,213<disabled><disabled>
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes6,191,148<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc